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In this month’s journal, Hoehn et al. present an important
analysis of patients with AJCC stage I and II hepatocellular
carcinoma (HCC) from the American College of Surgeons
National Cancer Data Base (NCDB) highlighting underutiliza-
tion and significant disparities in receipt of potentially curative
surgical therapy for HCC. Curative surgical therapies were
defined in this study as resection, transplantation and ablation,
which will collectively be referred to in this review as liver-di-
rected therapy (LDT). The authors provide additional evidence
of differential care for patients with HCC, namely LDT, based
on race/ethnicity, insurance and socioeconomic status and
facility type, and these findings testify in a timely manner to
fundamental inequalities in HCC management within the US
healthcare system.
A notable limitation of this study relates to the lack of
pertinent data used in clinical practice to make appropriate
treatment decisions, including LDT, for patients with HCC.
Optimal management of HCC is complex and influenced by
many interacting factors.1–5 Patient factors including perfor-
mance status, medical comorbidities, substance and alcohol
abuse, and treatment preferences influence recommended
care.3,4,6 In addition, liver-related factors including the pres-
ence of advanced liver disease and portal hypertension and
functional reserve impact treatment options, as do tumour-
related factors including stage, size and location.1,4,5 In gen-
eral, LDT should not be offered to patients with a poor per-
formance status or end-stage liver disease who would not
tolerate or benefit from such intervention.3,6 Further, cul-
tural, socioeconomic and geopolitical factors influence the
type of care recommended and received by patients with
HCC. For this reason, patients diagnosed with HCC should
be referred to a multidisciplinary care team encompassing
liver surgeons, hepatologists, radiologists, pathologists and
oncologists for consensus recommendations and to tailor a
treatment plan.3–5 Therapeutic interventions should also be
shaped by patient preference after they are educated about
the pros and cons and outcomes of various treatment
options.7
The authors’ state that ‘patients with stage I or II HCC are
curable’ and, therefore, candidates for LDT and that failure to
receive one of these LDTs constitutes underutilization of effec-
tive therapy. However, many patients with early stage HCC are
not curable based on advanced underlying liver disease or other
comorbid conditions that render the morbidity and mortality
associated with invasive LDT in excess of potential benefit with
regard to survival or improvement in quality life years gained.
Over 80% of HCC patients have underlying cirrhosis and may
not tolerate potentially curative therapy given an inadequate
liver reserve and the risk for decompensation. Hence, failure to
offer LDT to these patients should be regarded as appropriate,
rather than underutilized care. Unfortunately, the NCDB does
not collect data on many of the factors discussed above that
underlie decision-making in HCC, and, therefore, represents a
weakness of this study. It is not possible to know to what extent
appropriate curative care was unjustifiably or inequitably
withheld owing to non-medical reasons or whether curative
care was appropriately withheld because of any number of
tumour and/or medical reasons, including patient preference.
In contrast, disadvantaged populations are more likely to have
advanced cirrhosis owing to a lack of access to screening, pre-
ventive care and the management of liver disease and comor-
bidities, including substance abuse. It is, therefore, important to
note that the reason patients may not be candidates for poten-
tially curative therapy, namely the severity of underlying liver
disease, may also be related to race and socioeconomic status.
While rigorous, the multiple logistic regression model used
in this study to analyse predictors of LDT and 30-day mortal-
ity is weakened by use of AJCC stage I and II data, which are
entirely based upon tumour stage as opposed to other more
clinically useful staging systems such as the widely adopted
Barcelona Clinical Liver Cancer Study Group Staging system
which incorporates performance status, liver function, tumour
number and size.1–3 It is also curious that almost half of the
patients in the NCDB with stage I and II HCC reported in the
study by Hoehn had a Charlson score of zero because the pres-
ence of cirrhosis would account for at least one point in the
HPB 2015, 17, 745–746 ª 2015 International Hepato-Pancreato-Biliary Association
DOI:10.1111/hpb.12477 HPB
Charlson score. Therefore, the data presented by Hoehn are
not consistent with the demographics of HCC and suggest
there may be under-reporting of cirrhosis in the NCDB.
Despite weakness in the data source, it is clear from this and
other studies that utilization of potentially curative therapy for
HCC is limited, and that access is inequitable.8,9 However, only
a minority of patients with HCC meet the criteria to receive
surgical care, as outlined by established consensus guidelines.3–5
Nevertheless, fundamental disparities are known to exist across
the spectrum of HCC disease prevention, screening and man-
agement, all of which impact differential outcomes and sur-
vival.8,9 First, HCC disproportionately affects disadvantaged
populations with the highest incidence rates occurring among
ethnic minorities and those of low socioeconomic status who
have higher rates of chronic viral hepatitis, the leading risk fac-
tor for HCC, and diminished access to consistent medical
care.10 Given that HCC rates are rising, and the population of
ethnic minorities in the US is expanding, this is an increasingly
pertinent issue. Further, curative options are most often avail-
able for those with compensated liver disease diagnosed with
early stage HCC, as detected by routine surveillance which is
known to improve early tumour detection, delivery of curative
therapy and overall survival in patients with cirrhosis.11 It is
key to acknowledge that rates of guideline-consistent HCC
surveillance are inadequate overall, and there are significant
racial and socioeconomic disparities in receipt of surveil-
lance.12,13 Hence, improving preventive care, including access
to viral hepatitis therapy and cirrhosis management, will likely
have a greater impact on HCC survival and outcomes for
disadvantaged populations than expanding access to LDT.
Universal access to appropriate care across the spectrum of
liver disease is a key element of a high-value health care sys-
tem, and current disparities in access are a threat to such a
value. Hoehn’s study also reveals that care for patients with
HCC must be accessible in academic medical centres to be of
high value. While there are no data in the NCDB that disclose
why this may be the case, it is presumed that it is because aca-
demic centres are more likely than community hospitals to
have advanced technology (for both diagnosis and treatment)
and employ more experienced clinicians to deliver patient-
specific multidisciplinary therapy according to evidence-based
consensus guidelines.3–5 Great strides have been made to
improve outcomes and survival for patients afflicted with
HCC. Unfortunately, these advances in care appear to be
disproportionately shared in the United States. This paper adds
fuel to a fire that will hopefully accelerate change through
progressive health care reforms that translate to improved
care, ranging from prevention to cure, for disadvantaged
populations who bear the greatest burden of HCC.
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